Protagenic advances PT00114 into multiple-dose Phase 1 trial

Protagenic Therapeutics (PTIX) announced completion of first dose injection for all study subjects in the multiple-dose portion of its ongoing Phase I clinical trial of PT00114. The company expects to complete dosing by the end of August, with topline safety data anticipated by the end of September, supporting advancement into Phase 2 efficacy studies planned for the first quarter of 2026. PT00114 is the first investigational therapy based on Teneurin C-terminus Associated Peptide, a naturally occurring brain hormone localized in the amygdala and hippocampus that regulates stress and emotional balance. Unlike existing therapies that blunt symptoms, PT00114 is thought to directly modulate the brain’s maladaptive responses to stress-offering a differentiated approach to treating anxiety, depression, addiction, and Post Traumatic Stress Disorder. The multiple-dose study follows a single ascending dose trial that confirmed PT00114’s favorable safety and tolerability profile. Data from this trial will contribute to Phase 2 studies designed to demonstrate PT00114’s therapeutic potential in stress-related and mood disorders.